We have previously observed FOXP2 expression in multiple myeloma,[11] a plasma cell malignancy that is known to interact with the bone microenvironment and cause devastating lytic bone disease in patients.[29] The osteoblast transcription factor RUNX2 is also expressed in myeloma[30] and we hypothesised that similarly FOXP2 might play a role in normal bone biology. The gene discussed is RUNX2; the disease is plasma cell myeloma.